G-Protein Coupled Estrogen Receptor in Breast Cancer
AbstractThe G-protein coupled estrogen receptor (GPER), an alternate estrogen receptor (ER) with a structure distinct from the two canonical ERs, being ERα, and ERβ, is expressed in 50% to 60% of breast cancer tissues and has been presumed to be associated with the development of tamoxifen resistance in ERα positive breast cancer. On the other hand, triple-negative breast cancer (TNBC) constitutes 15% to 20% of breast cancers and frequently displays a more aggressive behavior. GPER is prevalent and involved in TNBC and can be a therapeutic target. However, contradictory results exist regarding the function of GPER in breast cancer, proliferative or pro-apoptotic. A better understanding of the GPER, its role in breast cancer, and the interactions with the ER and epidermal growth factor receptor will be beneficial for the disease management and prevention in the future. View Full-Text
Share & Cite This Article
Hsu, L.-H.; Chu, N.-M.; Lin, Y.-F.; Kao, S.-H. G-Protein Coupled Estrogen Receptor in Breast Cancer. Int. J. Mol. Sci. 2019, 20, 306.
Hsu L-H, Chu N-M, Lin Y-F, Kao S-H. G-Protein Coupled Estrogen Receptor in Breast Cancer. International Journal of Molecular Sciences. 2019; 20(2):306.Chicago/Turabian Style
Hsu, Li-Han; Chu, Nei-Min; Lin, Yung-Feng; Kao, Shu-Huei. 2019. "G-Protein Coupled Estrogen Receptor in Breast Cancer." Int. J. Mol. Sci. 20, no. 2: 306.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.